Neurocrine Biosciences (NBIX)

• Market cap: $10B
• 1 day: 1.28%
• 5 days: 12.08%
• 1 month: -9.08%
• 3 months: -29.23%
• 6 months: -14.42%
• Year to date: -26.46%
• 1 year: -23.91%
• 5 years: 2.45%
• 10 years: 138.60%
• Sector: Healthcare
• Industry: Drug Manufacturers - Specialty & Generic

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

51% more first-time investments, than exits

New positions opened: 109 | Existing positions closed: 72

21% more capital invested

Capital invested by funds: $10.7B [Q3] → $12.9B (+$2.2B) [Q4]

20% more funds holding in top 10

Funds holding in top 10: 10 [Q3] → 12 (+2) [Q4]

4% more funds holding

Funds holding: 564 [Q3] → 587 (+23) [Q4]

1.44% more ownership

Funds ownership: 91.71% [Q3] → 93.15% (+1.44%) [Q4]

9% more call options, than puts

Call options by funds: $48M | Put options by funds: $44.2M

3% more repeat investments, than reductions

Existing positions increased: 212 | Existing positions reduced: 206

Research analyst outlook

10 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $137 35% upside
• Avg. target: $158 56% upside
• High target: $185 82% upside

10 analyst ratings

• positive: 10 100%
• neutral: 0 0%
• negative: 0 0%

Needham Ami Fadia 13% 1-year accuracy 22 / 164 met price target	36% upside $138	Buy Upgraded	15 Apr 2025
RBC Capital Brian Abrahams 3% 1-year accuracy 2 / 66 met price target	35% upside $137	Outperform Upgraded	14 Apr 2025
UBS Ashwani Verma 5% 1-year accuracy 1 / 19 met price target	35% upside $137	Buy Maintained	4 Apr 2025
JP Morgan Anupam Rama 15% 1-year accuracy 9 / 61 met price target	82% upside $184	Overweight Maintained	26 Mar 2025
Morgan Stanley Jeffrey Hung 8% 1-year accuracy 2 / 26 met price target	48% upside $150	Overweight Assumed	7 Mar 2025